Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer

Diagnostic Oncology: Reports from the IASLC Pathology Committee

The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?

The Future Is Now: Pathology Is Going Digital

Enhancing Understanding of Testing Applications, Best Practices: A Q&A with Dr. Lynette M. Sholl

Low-Dose CT, ctDNA May Partner for Lung Cancer Detection

Award Lecture Highlights Tumor Evolution Through Liquid Biopsy

Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist

Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye

Recurrence Remains a Risk Even for Patients Diagnosed via Screening

New Data Support Continued Use of IASLC Staging Model for Mesothelioma